Publication: Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination.
Loading...
Identifiers
Date
2022-11-26
Authors
Molina-Ramos, Ana I
Gomez-Moyano, Elisabeth
Rodriguez-Capitan, Jorge
Angullo-Gomez, Maria
Gallardo-Jimenez, Patricia
Perez-de-Pedro, Ivan
Valiente-de-Santis, Lucia
Perez-Villardon, Beatriz
Piñero-Uribe, Isabel
Mora-Robles, Javier
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
Description
MeSH Terms
SARS-CoV-2
Prognosis
Vaccination
Health Status
Prognosis
Vaccination
Health Status
DeCS Terms
Miocarditis
Epidemiología
SARS-CoV-2
Coronavirus
Salud pública
Vacunas de ARNm
Epidemiología
SARS-CoV-2
Coronavirus
Salud pública
Vacunas de ARNm
CIE Terms
Keywords
COVID-19, mRNA vaccines, Myocarditis
Citation
Molina-Ramos AI, Gómez-Moyano E, Rodríguez-Capitán J, Angullo-Gómez M, Gallardo-Jiménez P, Pérez de Pedro I, et al. Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination. J Clin Med. 2022 Nov 26;11(23):6999